Locally Advanced/ Metastatic NSCLC
Conditions
Brief summary
Vinorelbine is the first line reference drug in the elderly patient with locally advanced / metastatic non-small-cell lung cancer (NSCLC). The introduction of the oral formulation of vinorelbine has determined a further impulse to its use in 1st line and above all to its use as metronomic therapy. Metronomic chemotherapy offers the advantage of increasing the overall dosage of the drug administered, but reducing the side effects or making them more easily manageable; it is practically a question of administering fractionated doses of the drug continuously for long periods (generally up to the progression of unacceptable disease or toxicity). This study collects data on the efficacy and tolerability of oral metronomic vinorelbine in elderly patients with NSCLC, performed as per normal clinical practice.
Detailed description
Vinorelbine is the first line reference drug in the elderly patient with locally advanced / metastatic non-small-cell lung cancer (NSCLC). The introduction of the oral formulation of vinorelbine has determined a further impulse to its use in 1st line and above all to its use as metronomic therapy. Metronomic chemotherapy offers the advantage of increasing the overall dosage of the drug administered, but reducing the side effects or making them more easily manageable; it is practically a question of administering fractionated doses of the drug continuously for long periods (generally up to the progression of unacceptable disease or toxicity). This study collects data on the efficacy and tolerability of oral metronomic vinorelbine in elderly patients with NSCLC, performed as per normal clinical practice.
Interventions
DRUGVinorelbine
Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks. Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously. The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion).
Sponsors
Azienda Sanitaria Ospedaliera
International Group of Endovascular Oncology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Inclusion criteria
* Patients with a diagnosis of histologically documented NSCLC (adenocarcinoma and squamous carcinoma), stage IIIB (not eligible for surgery or chemo-radiotherapy) and stage IV according to the 8th edition of TNM * Wild type for EGFR, ALK and PDL-1 * Age ≥ 70 years * PS 0 - 2 * Adequate medullary reserve (neutrophils\> 1500; PLT\> 100,000 mm3); hepatic / renal function preserved * Written informed consent
Exclusion criteria
* Gastrointestinal disorders that contraindicate the intake of the capsules (type ulcerative colitis or Chron's disease). * Performance Status ECOG ≥ 3
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TUMOR RESPONSE | 6 MONTHS | STABLE DISEASE |
| number of adverse events | 6 MONTHS | TOLERANCE TO VINORELBINE |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1 year | PROGRESSION FREE SURVIVAL |
| OS | 1 YEAR | OVERALLA SURVIVAL |
Countries
Italy
Contacts
Primary ContactDAVID ROSSI, MD
Outcome results
None listed